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Hepatocellular carcinoma (HCC) is one of the most frequent
human malignancies with poor prognosis and increasing inci-
dence in the Western world. Only for a minority of HCC patients,
surgical treatment options offer potential cure and therapeutic
success of pharmacological approaches is limited. Highly speciﬁc
approaches (e.g., kinase inhibitors) did not signiﬁcantly improve
the situation so far, possibly due to functional compensation,
genetic heterogeneity of HCC, and development of resistance
under selective pressure. In contrast, transcriptional regulators
(especially transcription factors and co-factors) may integrate
and process input signals of different (oncogenic) pathways and
therefore represent cellular bottlenecks that regulate tumor cell
biology. In this review, we want to summarize the current knowl-
edge about central transcriptional regulators in human hepato-
carcinogenesis and their potential as therapeutic target
structures. Genomic and transcriptomic data of primary human
HCC revealed that many of these factors showed up in subgroups
of HCCs with a more aggressive phenotype, suggesting that aber-
rant activity of transcriptional regulators collect input informa-
tion to promote tumor initiation and progression. Therefore,
expression and dysfunction of transcription factors and co-factors
may gain relevance for diagnostics and therapy of HCC.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
With more than 500,000 new cases each year, hepatocellular
carcinoma (HCC) is one of the leading causes of cancer-related
death [1]. Its risk factors are well deﬁned (e.g., chronic viral hepa-
titis, alcoholic and non-alcoholic steatohepatitis, aﬂatoxin incor-
poration, and several hereditary diseases) and are detectable in
up to 90% of all cases. Unfortunately, genetic heterogeneity ofJournal of Hepatology 20
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drugs,which is reﬂected by the current lack of therapeutic options.
For few patients, partial hepatic resection or liver transplanta-
tion offers potential cure and only the multi-kinase inhibitor
sorafenib has been established as the ﬁrst effective and approved
systemic treatment for progressed HCC [2]. Interestingly, func-
tional genomics revealed that dysregulation of some signalling
pathways (e.g., WNT-, IGF/IGF-1R, HGF/c-MET) characterizes sub-
groups of HCCs with speciﬁc clinical and biological features
[1,3–5], suggesting that receptor-mediated signalling cascades
may represent promising therapeutic target structures. However,
the ﬁrst clinical trials indicated that administration of monoclo-
nal antibodies and kinase inhibitors targeting different tumor-
relevant receptors did not further improve the situation [6]. For
this reason, the identiﬁcation of targets that modulate/regulate
different oncogenic pathways in HCC and accordingly direct drug
development are of high relevance for improvement of the cur-
rent dismal and unsatisfactory situation.
Transcription factors and transcriptional co-factors convert
and integrate extra- and intracellular signals and therefore repre-
sent central regulators of cellular processes in normal and malig-
nantly transformed cells. About 10% of all human genes code for
proteins containing DNA-binding domains; most of these pro-
teins may function as transcription factors and co-factors, which
are pivotal for ﬁne-tuning regulation of the transcriptional
machinery. Basically, eukaryotic mRNA transcription is divided
into three steps: (1) binding of transcriptional activators to cis-
acting DNA sequences, (2) recruitment of the pre-initiation
complex to the core promoter, and (3) elongation of the mRNA
molecule [7]. In this system, general transcription factors (e.g.,
TFIIA and TFIIH) are sufﬁcient for basal transcription and form
(together with RNA polymerase II) the pre-initiation complex at
the core promoter region. Speciﬁc transcription factors bind addi-
tional DNA motifs (e.g., enhancers and silencers), which are in
most cases located in the vicinity of the core promoter [8]. Initi-
ation, progression, and termination of this highly complex pro-
cess as well as classiﬁcation of the different speciﬁc
transcription factors and co-factors have been studied in detail
(see [9–11]). One key feature of transcriptional regulation is that
most of these proteins remain as inactive forms in the cytoplasm
until they translocate in the nucleus upon stimulation. In tumor
cells, activation or aberrant expression of these factors frequently
represents the last step in a number of signalling pathways that
affect proliferation, apoptosis, differentiation, migration, or
senescence in an oncogenic manner.12 vol. 57 j 186–195
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Dysregulation of many transcription factors and transcrip-
tional co-factors such as FBPs [12], YAP [13], STAT3 [14], SMADs
[15], NF-kB [16], FOXM1 [17], and ATF5 [18] has been described
in human hepatocarcinogenesis; however, it is difﬁcult to spot
key factors that deﬁne the biological behaviour and the clinical
outcome of human HCC. For this reason, this review focuses on
factors that – based on comprehensive proﬁling analyses – may
deﬁne subgroups of HCCs with speciﬁc characteristics: c-Myc,
b-Myb, b-catenin, AP-1, p53, HIF-1a, E2F, and HOX. Although
these regulators of transcription have been regarded as ‘‘non-dru-
gable’’, due to the large and stable protein/DNA surface interac-
tion, some approaches for the speciﬁc inhibition of these factors
have been developed during the last decade. In the following sec-
tions, we brieﬂy summarize the current knowledge about these
transcriptional regulators in human hepatocarcinogenesis and
their potential as therapeutic targets. We did not include the dif-
ferent relevant animal models that further underline the rele-
vance of transcriptional regulators; most of these models have
been comprehensively analysed in other studies (e.g., [19,20]).
 
 
 
 
 
Key Points 
• 
transcriptional regulators as frequently dysregulated in 
hepatocarcinogenesis: c-Myc, b-Myb, β-catenin, AP-1, 
p53, HIF-1α, E2F, and HOX
• 
subgroup of HCCs with a more aggressive phenotype
• Based on their central and integrative position in tumor-
supporting signalling cascades, transcriptional regulators 
represent promising therapeutic targets
Comprehensive profiling of human HCCs identified
Dysregulation of transcriptional regulators defines aTranscriptional regulators in human hepatocarcinogenesis
Identiﬁcation of key integrators using functional genomics
Dysregulation of several transcription factors and co-factors has
been described in the context of human HCC; however, functional
genomics approaches on primary human HCCs revealed that
aberrant expression of some factors was characteristic of sub-
groups of HCCs with speciﬁc biological and clinical features
(Table 1). Transcriptional analyses as well as integrative
approaches (further including genomic, mutational, and protein
data) demonstrated that c-Myc, b-Myb, b-catenin, AP-1, p53,
HIF-1a, E2F, and HOX may play key roles in hepatocarcinogenesis
[3,4,21,22]. Many of these factors are known regulators of central
protumorigenic cellular processes in HCC cells such as prolifera-
tion (c-Myc, b-Myb, b-catenin, AP-1, p53, HIF-1a, E2F), (anti-)
apoptosis (c-Myc, b-Myb, AP-1, p53, E2F, HOX), and migration/
invasion (b-catenin, HOX).
Based on meta-analysis of existing gene expression proﬁles,
preferential accumulation of E2F1, c-Myc, and increased nuclear
expression of p53 were detected in groups of HCCs characterized
by high tumor cell proliferation, dedifferentiation, and dismal
prognosis [4]. The central role for c-Myc has been further sub-
stantiated by the identiﬁcation of c-Myc-dependent target gene
signatures (based on copy number gains of 8q24), which were
signiﬁcantly enriched in early human HCCs but not in premalig-
nant lesions, suggesting that dysregulation of c-Myc and its tar-
get genes is also critically involved in malignant transformationJournal of Hepatology 201[23]. In addition, c-Myc-dependent signatures of four microRNAs
are characteristic of HCCs with a more aggressive phenotype [24].
Comprehensive expression proﬁling revealed overexpression of
b-Myb in HCCs where it belongs to a cluster of genes associated
with cell cycle progression and proliferation [25]. The role of p53
is supported by previous integrative studies, which revealed that
mutations in TP53 deﬁne a subgroup of HCCs characterized by
chromosome instability and poor differentiation [3,26]. In addi-
tion, elevated HIF-1a and HOXA13 levels in a subgroup of
patients correlated with poor prognosis [3,21,27]. HCCs charac-
terized by a fetal hepatoblast-like expression signature and poor
patient prognosis showed overexpression of AP-1 subunits (e.g.,
c-Fos and Fra-2) and upregulation of c-Jun/c-Fos-dependent tar-
get genes [22]. However, these analyses did not yield a uniform
picture for an activation of b-catenin. On one hand, it has been
shown that HCCs with b-catenin mutations are characterized by
large tumor size and low genomic instability [26] and that ele-
vated b-catenin expression (associated with a WNT signature)
deﬁned a group of dedifferentiated HCCs with a more aggressive
phenotype [4]. In contrast, in another study, subgroups withWNT
activation exhibited better prognosis than groups without activa-
tion [3].
v-myc avian myelocytomatosis viral oncogene homolog (c-Myc)
The proto-oncogene c-Myc potentially interacts with up to 15% of
mammalian gene promoters; thus it is involved in a plethora of
biological processes such as cell growth and cell cycle, metabo-
lism, programmed cell death, cell adhesion, DNA repair, as well
as microRNA regulation. Heterodimerization with its binding
partner Max and interaction with several co-regulators (e.g.,
SWI/SNF) are essential for efﬁcient induction of transcription
and probably target gene speciﬁcity. While Max is ubiquitously
expressed in many cell types, c-Myc abundance is tightly con-
trolled and therefore deﬁnes the activity of the c-Myc/Max com-
plex [28].
In HCC, c-Myc is reported to be overexpressed in 47–65% of all
cases [29,30]. Elevated c-Myc levels are predominantly based on
chromosomal gains of the Myc gene locus (8q24.21), which were
detected in up to 60% of all the cases [31,32] and which corre-
lated with dedifferentiation and poor patient prognosis [32].
Interestingly, array-CGH data revealed signiﬁcantly elevated copy
number gains and c-Myc overexpression in alcohol-related HCCs,
while no chromosomal changes were detectable in cryptogenic
HCCs that are thought to be caused by non-alcoholic steatohepa-
titis [33]. Besides genomic gains, HBV- and HCV-derived proteins
(HBx and core protein, respectively) may induce c-Myc expres-
sion [34,35], indicating that hepatocarcinogenic viruses may have
developed independent ‘‘epigenomic’’ mechanisms to further
support c-Myc expression.
v-myb myeloblastosis viral oncogene homolog (avian)-like 2 (b-
Myb)
b-Myb (synonym: MYBL2) belongs to the Myb proto-oncogene
family. It directly binds to the consensus MYB-binding site of
gene promoters or interacts with other transcription factors
(e.g., SP1) to regulate the expression of target genes [36]. More-
over, in conjunction with E2F, b-Myb regulates gene transcription
control during cell cycle progression [37].
In HCC, b-Myb overexpression was detectable in more than
90% of all the analyzed cases predominantly based on genomic2 vol. 57 j 186–195 187
Table 1. Transcriptional regulators in human hepatocarcinogenesis.
Protein (Gene) Frequency 
(%)
Function Mode of dysregulation [Ref.]
p53 (TP53) mutations 10-48 
genomic: 30
Proliferation, apoptosis, senescence, 
DNA mismatch repair
Genomic gains
gain/loss of function mutations 
altered upstream regulators
[62, 64-65] 
MDM2: up: 40%
c-fos (FOS) up: 48-91 Proliferation, apoptosis, differentiation n.d. [55, 57, 122]
c-jun (JUN) up: 91 Proliferation, apoptosis, differentiation n.d. [57]
junB (JUNB) down: 73-80 Proliferation, apoptosis, differentiation n.d. [56, 58]
β-catenin (CTNNB1) mutations: 13-43 Proliferation, differentiation, migration Mutations [3, 29, 123]
Axin1/2: mut: 5-15% [43]
FZD3/6/7; WNT3/4/5a: mutations: 
90%
[45, 124]
SFRP1: down: 92% [125]
DKK: up: 40% [126-127]
PIN1: up: 50% [128]
HDPR1/Dapper: down: 43% [129]
TCF/LEF-1: up: 52% [49]
c-Myc (MYC) up: 47-65 Proliferation, apoptosis, differentiation [29-30, 33]
b-Myb (MYBL2) up: 90 Proliferation, apoptosis [38, 40]
HOXA13 (HOXA13) up: 100 (mRNA)
up: 16 (protein)
n.d. Polysomy of chromosome 7 [27]
HOXA5 (HOXA5) up: 83 (mRNA) n.d. Polysomy of chromosome 7 [27]
HOXA7 (HOXA7) up: 75 (mRNA) n.d. Polysomy of chromosome 7 [27]
HOXB5 (HOXB5) up: 42 (mRNA) n.d. Polysomy of chromosome 7 [27]
HOXD3 (HOXD3) up: 83 (mRNA) n.d. Polysomy of chromosome 7 [27]
HIF-1α (HIF1A) up: 67 Proliferation, angiogenesis, 
anti-apoptosis,
Growth factor activation 
impaired degradation
[73]
E2F1 (E2F1) overexpressed Anti-apoptosis
reduction of Rb levels
[38, 62, 84, 130]
E2F3 (E2F3) up: 71 Apoptosis Regulation by microRNA [81, 131]
E2F8 (E2F8) up: 65 Proliferation, colony formation n.d. [80]
Amplification: 55%, induced by E2F1
Amplification: 60%
Amplification: 22%
up, upregulated; down, downregulated; n.d., not determined.
Reviewgains of the MYBL2 gene locus (chr. 20q13.1) and transcriptional
activation by E2F1 [38]. Its elevated expression in HCC tissues
correlated with p53 staining (indicating mutations) and vascular
invasion [25]. In addition, overexpression of b-Myb increased cell
viability of HCC cell lines [39]. Recently, it was shown that in HCC
tissues the expression and especially the phosphorylation/activa-
tion of b-Myb signiﬁcantly and positively correlated with prolif-
eration, genomic instability, and microvessel density. In
addition, b-Myb levels were higher in HCC patients with poor
prognosis [40]. Interestingly, b-Myb seems to be involved in the
induction of DNA repair mechanisms and integrity of a b-Myb/
LIN9 complex contributes to the survival of p53-deﬁcient HCC
cells [40].
b-catenin
Activation of the Wingless (Wnt) pathway leads to the nuclear
translocation of the transcriptional co-regulator b-catenin, where
it interacts with the T-cell factor (TCF)-/lymphoid-enhancer fac-
tor (LEF) transcription factor that regulates cell cycle progression,188 Journal of Hepatology 201differentiation, and cell motility. In the absence of pathway acti-
vation, aminoterminal phosphorylation of b-catenin by the APC/
Axin/GSK-3b complex leads to its polyubiquitination and subse-
quent degradation [41].
More than 40% of all HCCs exhibit nuclear accumulation of b-
catenin, which is in most cases explained by stabilizing point
mutations and deletions in its N-terminal domain [3,29,42]. In
addition, inactivating mutations in components regulating b-
catenin degradation such as Axin-1, Axin-2 [43] and GSK-3b have
been detected as well as overexpression of the APC-complex reg-
ulating factors (e.g., Dvl3 [44]), and different WNT ligands and
receptors (e.g., FRZ7; [45]). Interestingly, APC mutations – which
are frequent events in gastric and colorectal cancer [46] – are rare
in human HCCs [47,48]. Next to the aberrant activation of b-cate-
nin, accumulation of its transcriptional binding partners has been
shown in many HCCs (e.g., nuclear accumulation of LEF-1/TCF in
52% [49]). Several additional factors which are known modiﬁers
of Wnt/b-catenin activity such as DKK, HDPR1/dapper, and PIN1
are also dysregulated in HCC, clearly demonstrating that in most
cases synchronous activation of different pathway components2 vol. 57 j 186–195
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and regulators is necessary to achieve complete pro-tumorigenic
capacity of the pathway.
Both, HBV and HCV infections may stimulate the Wnt/b-cate-
nin pathway by independent and virus-speciﬁc mechanisms.
While HCV-positive HCC patients showed high frequency muta-
tions in CTNNB1 [50,51], other data suggested that HBV may acti-
vate this pathway in a mutation-independent manner due to
expression of HBx-induced host proteins that stabilize b-catenin
[51,52].
Activator protein-1 (AP-1)
The activating protein-1 (AP-1) transcription factor collectively
describes a family of functionally and structurally related hetero-
dimeric complexes composed of varying combinations of, for
example, Jun (c-Jun, Jun-B, Jun-D) and Fos (c-Fos, Fos-B, Fra-1,
Fra-2) proteins [53]. They are typically activated by growth fac-
tor/receptor tyrosine kinase pathways and, based on their speciﬁc
composition, regulate proliferation, apoptosis, and differentiation
under physiological conditions and in tumorigenesis [54].
Although overexpression of c-Fos and c-Jun has been
described in human HCC [55–57], increasing evidence indicates
that AP-1 constituents may also provide tumor-suppressive
activity under speciﬁc conditions [54]. For HCC, this was exempli-
ﬁed by JunB, which is frequently reduced in HCCs compared to
surrounding non-tumorous tissues [58]. Nevertheless, a gradual
increase in the DNA binding capacity of AP-1 has been detected
in peritumoral and HCC tissues compared to histologically nor-
mal liver samples, indicating that aberrant activation of AP-1 dur-
ing human hepatocarcinogenesis may be involved in hepatocyte
transformation and tumor progression [59].
In addition to the aberrant expression of AP-1 subunits, phos-
phorylation/activity of AP-1 constituents is regulated by a broad
spectrum of stimuli that control the MAPK pathway. Especially
Jun N-terminal kinase (JNK)-1 has been described to contribute
to hepatocarcinogenesis. Studies demonstrated increased activa-
tion of JNK-1 in more than 50% of HCCs [60] and correlation of
high JNK-1 level with poor patient survival [61].
p53
Mutations in the TP53 gene (which codes for the tumor suppres-
sor p53) are likely to be the most frequent tumor-relevant
mutations deﬁned in human malignancies. In human hepatocar-
cinogenesis, multiple mechanisms can be associated with func-
tional inactivation of wild type p53 (p53wt). First, more than
30% of all HCCs show chromosomal losses of the TP53 gene locus
(17p13.1) [62]. Second, viral proteins with transforming capacity
(e.g., HBV-derived HBx-Ag) bind and inactivate p53wt [63]. Third,
inactivation of p53 by point mutations or small deletions is
detectable in 10–28% of Western world HCCs. However, in areas
with high aﬂatoxin-B1 exposure, the incidence of codon 249
(p53mut249) transversions may be present in as much as 50% of
all HCCs and represents one of the earliest and most clear-cut
examples of molecular cancer epidemiology [64,65]. Since p53
binds DNA as a tetramer, mutated p53mut249 exhibits a dominant
negative effects on p53wt with regard to cell survival and cell
cycle control [66]. In addition, various gain of function mutations
have been identiﬁed in human (hepato-)carcinogenesis that facil-
itate tumor-promoting activity of p53mut at different stages of
tumor progression as well as resistance to cancer treatmentJournal of Hepatology 201[67]. Lastly, aberrant expression and activity of factors that regu-
late p53 stability (e.g., the E3 ubiquitin ligase MDM2, which tar-
gets p53 for proteasomal degradation) may affect its availability
[33,68]. Because concentrations and activity of p53 are affected
by many molecular mechanisms at different levels in HCC, it is
likely that in most (if not all) HCCs the biological integrity of
the p53 pathway is somehow impaired. However, respective
comprehensive studies comparing the frequency of the different
modes of p53 dysregulation in human HCC are missing so far.
Increasing data indicate that full length isoforms of p63 and
p73 (TAp63 and TAp73), which are structurally related to
p53wt, can partly mimic its function. In HCC cells, p53mut directly
binds to TAp63/TAp73 and subsequently decreases their pro-
apoptotic features [69,70]. It is therefore likely that next to the
mutational status of p53, an altered ratio between p53 and p73
(TAp73 and the shorter DNp73) and/or p63 (TAp63 and the
shorter DNp63) inﬂuences p53-dependent effects and chemosen-
sitivity in HCC patients.
Hypoxia-inducible factor-1 (HIF-1)
Hypoxia induces the activity of the heterodimeric transcription
factor HIF-1. In contrast to the constitutively expressed subunit
HIF-1b, HIF-1a is degraded in a proteasome-dependent manner
under normoxic conditions by post-transcriptional prolyl hydrox-
ylation. Hypoxia prevents this protein from being degraded,
resulting in increased HIF-1a levels and induction of HIF-1-regu-
lated genes that may promote angiogenesis, metabolic processes,
and cell survival [71].
Hypoxic tumor microenvironment, as a result of uncontrolled
tumor cell growth, and subsequent hypervascularisation are fre-
quently observed in moderately and poorly differentiated tumors
[72]. In these cases, high-level expression of HIF-1awas observed
in more than 60% of HCC tissues, which correlated with poor
patient prognosis [73]. Interestingly, elevated HIF-1a transcript
levels in adjacent non-tumorous liver tissues correlated with
poor disease-free and overall survival of HCC patients, indicating
a paracrine effect of hypoxia even on non-tumorous cells [74].
In HCC, stabilization of HIF-1a in hypoxic-dependent and
independent manners is achieved by different mechanisms. First,
activation of typical growth factor-pathways promotes HIF-1a
stabilization (e.g., HGF/c-MET signalling) [75,76]. Second, HIF-
1a is stabilized after infection with HCV through impairment of
mitochondrial phosphorylation and subsequent metabolite-med-
iated inhibition of HIF-1a-prolyl hydroxylation [77]. Third, over-
expression of the oncoprotein gankyrin (p28GANK) in HCCs
induces HIF-1a [78].
E2F transcription factors
The activity of many E2F transcription factor family members
(E2F1-E2F8) is tightly regulated by the tumor suppressor retino-
blastoma (Rb). While hypophosphorylated Rb binds and inacti-
vates E2Fs, hyperphosphorylated Rb releases E2Fs which
heterodimerize with DP (E2F dimerization partner) transcription
factor family members. E2F1-E2F3a predominantly activate gene
expression, while E2F3b-E2F8 are referred to as transcriptional
repressors. Since E2Fs regulate key tumor-relevant processes in
a differential manner (e.g., cell proliferation and apoptosis), these
factors may exert oncogenic and tumor suppressive functions
[79].2 vol. 57 j 186–195 189
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So far, E2F1, E2F3, and E2F8 have been described as overex-
pressed in human HCC compared to non-tumorous liver tissues
[38,80,81]; however, different modes of dysregulation have been
detected so far. First, reduction of Rb levels (e.g., due to expres-
sion of viral proteins and chromosomal losses of the Rb gene)
may lead to enhanced E2F activity [62,82]. Second, reduction of
regulatory microRNAs (e.g., miR-195), which may lead to
increased E2F3 expression [81]. Third, genomic gains, microsatel-
lite instability, and deletion mutations in the E2F genes (e.g., for
E2F1 and E2F4) are commonly detected in HCC [83,84].
Homeobox (HOX) proteins
The homeobox gene family is involved in specifying positional
and spatio-temporal information during embryogenesis in mam-
malian cells. The 39 HOX genes are organized in four clusters on
separated chromosomes and are expressed in an organ- and tis-
sue-speciﬁc manner in embryonic and adult cells [85].
Accumulating data suggest the relevance of HOX gene dysreg-
ulation in human carcinogenesis as was shown for different solid
tumors and leukemia [86]. Recent publications also linked aber-
rant HOX protein expression with human hepatocarcinogenesis
[27,87]. Most HOX genes – especially HOXA5 and HOXA13 – were
upregulated at the mRNA level in HCC compared to non-cancer-
ous livers, possibly via a common mechanism [87]. Functional
data of HOX proteins in HCC cells are missing so far, but studies
in other tumor entities suggested that these factors regulate
apoptosis, receptor signalling, and invasion [86]. For HCC, a phys-
ical interaction of HOXA13 with eIF4E and its possible role in the
selective nuclear export of tumor-relevant transcripts have been
described (e.g., Cyclin D1, c-Myc, and VEGF) [27].
In summary, high throughput screening approaches revealed
groups of HCCs that are characterized by activation of transcrip-
tional regulators; for some proteins their tumor-supporting prop-
erties have been analyzed in detail (e.g., b-catenin, p53, c-Myc),
while for others comprehensive expression data, mode of dysreg-
ulation, and functional effects in HCC cells are largely missing
(e.g., HOX family members).
More importantly, these data suggest that the coordinated
activation of transcriptional regulators is a frequent characteristic
of more aggressive HCCs (high proliferation, dedifferentiation,
large tumor size, poor survival), while it is not a key feature of
less aggressive HCCs. These signatures are more than surrogate
markers of speciﬁc signalling pathways dysregulated in HCC,
since their activation may be regulated by very different mecha-
nisms and partly by signalling pathway-independent stimuli
(e.g., E2F overexpression due to genomic gains, aberrant micro-
RNA expression, and loss of Rb function).
One limitation is that current expression proﬁling analysis
may consider genomic, transcriptomic, and (to a lesser extent)
proteomic information; however, the activity of transcriptional
regulators not only is deﬁned by their expression but also by their
subcellular distribution. Although some studies linked the dys-
regulation of speciﬁc factors with their cellular distribution
(e.g., b-catenin [3]), a comprehensive analysis integrating mRNA
and protein levels together with subcellular localization is miss-
ing so far. Some potentially relevant factors such as NF-kB, FBPs,
STATs, YAP, and SMAD2/4 have not shown up in any of the pro-
ﬁling studies so far, since they are only moderately regulated or
their oncogenic activation is not dysregulated at the expression190 Journal of Hepatology 201level. In these cases, mutations or post-transcriptional/transla-
tional regulation and modiﬁcation may account for aberrant
accumulation of transcriptional regulators. It would be interest-
ing to see whether activation or nuclear localization of these fac-
tors is more or less frequent in subgroups of HCCs with speciﬁc
gene signatures.Implications for targeted therapy
The differential diagnostic and clinical relevance of transcription
factors and co-factors in hepatocarcinogenesis was supported by
different proﬁling approaches partly integrating genomic and
transcriptomic data. These studies not only deﬁned subgroups
of HCCs with characteristic clinical and biological features but
also allocated aberrant activation/expression of signature tran-
scriptional regulators (b-catenin, AP-1, HIF1, c-Myc, b-Myb, E2F,
and p53) to HCCs with a more aggressive phenotype [3,4,21,22,
26]. These observations have further substantiated the integra-
tive character of transcriptional regulators and their ability to
incorporate independent stimuli into a ﬁnal oncogenic stimulus.
It also implicates that dysregulation of these factors may put
their stamps on the expression proﬁles and the biology of speciﬁc
HCC subgroups – this qualiﬁes these factors as potential molecu-
lar markers.
In highly heterogeneous carcinomas, broader inhibition of
oncogenic mechanisms may turn out to be more efﬁcient com-
pared to highly speciﬁc blocking of single pathways components
such as receptor tyrosine kinases [6]. In principle, transcriptional
regulators may represent attractive target structures in cancer
therapy, since their activity integrates the activation of many
pathways representing the bottleneck and ﬁnal instance before
transcriptional activation results in an oncogenic phenotype.
However, targeting transcription factors in cancer raises impor-
tant issues:
(1) Although global inhibition of transcription factors may
cause acceptable unwanted effects [88], tumor cell-speciﬁc
targeting is preferable. Systemic approaches might cause
severe side effects under speciﬁc physiological conditions
(e.g., regeneration).
(2) At least in some cases, targeting approaches have to dis-
criminate between structurally related proteins, since
different family members facilitate distinct biological
features (e.g., AP-1 subunits). Blocking entire protein
families may lead to uncontrolled and even opposite
effects.
(3) Transcriptional regulators lack enzymatic activity; thus,
protein-directed inhibitors may have to disturb large sur-
face protein/protein or protein/DNA interaction structures
(e.g., c-Myc/Max heterodimers) posing additional chal-
lenge, e.g., on lead substance optimization.
Despite these obstacles, successful methods targeting onco-
genic transcription factors’ activity have been developed leading
to promising strategies (Fig. 1), which do not rely on the pharma-
cological inhibition of upstream regulators (e.g., receptor tyrosine
kinase inhibitors [6]) or virus-mediated re-expression of pathway
antagonists that are silenced in HCC (e.g., the WNT pathway
antagonist Wst-1 [89,90]).2 vol. 57 j 186–195
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Fig. 1. Modes of dysregulation of transcriptional regulators (TR) in human HCC cells (red) including mutations of upstream signalling pathway components (e.g.,
receptors and pathway constituents), mutations, and genomic alterations. Possibilities of pathway interference (blue) include the inhibition of receptor tyrosine kinase
(RTK) inhibitors, expression of pathway antagonists, and inhibitors of TR-dimerization and TR/DNA interaction. Virotherapy links TRs activity with viral replication and
oncolysis.
JOURNAL OF HEPATOLOGYChemical compounds targeting transcription factor activity
and expression
Some methodological approaches utilize small organic molecules
that speciﬁcally inhibit the interaction between transcription fac-
tors and their respective DNA-binding domains. In addition, sev-
eral transcription factors form hetero- or homodimers (e.g., AP-1,
Myc/Max, HIF-1a/HIF-1b) as well as multimers (e.g., p53) in
order to recognize and bind their respective DNA binding sites.
Disturbing these protein/protein interactions by speciﬁc sub-
stances may destabilise transcriptional complex assembly and
thereby inhibit dysfunctional transcriptional activity.
For both approaches, low-molecular-weight compounds
should overcome high-afﬁnity interaction between transcription
factors and their DNA recognition motif or protein/protein inter-
faces. For many transcriptional regulators, various pharmacolog-
ical substances have been developed and tested in different
in vitro and/or in vivo cancer models. These include compounds
targeting c-Myc/Max (e.g., substance 10058-F4 [91]), FBP (com-
pound 1 [92]), STAT3 (e.g., ISS 610 [93,94]), and b-catenin/TCF
(e.g., PKF115–584 [95]). Some of these substances have already
been successfully tested using HCC cells (e.g., 10058-F4 [96]).
For some factors, such as HIF-1, for which the design of spe-
ciﬁc drugs inhibiting protein/DNA or protein/protein interaction
has been less successful (reviewed in [97]), the lack of speciﬁcity
of the employed substances favoured approaches that indirectly
regulate HIF-1 concentrations, e,g. compounds that affect HIF-1
expression (transcription and translation) and stability (e.g., YC-
1 [98]).Journal of Hepatology 201Because most p53 mutations represent missense mutations
affecting its DNA binding domain, pharmacological reactivation
of p53mut isoforms may induce apoptosis and senescence of
tumor cells. Screening of chemical libraries and rational design
of substances that stabilize the wild type conformation of
mutated p53 have led to the identiﬁcation of small molecules
that bind p53mut and restore its tumor suppressive function
(e.g., PhiKan083 and PRIMA-1; reviewed in [99]). In addition,
reconstitution of wild type p53 activity in tumors without p53
mutations (but e.g., with MDM2 overexpression) was achieved
by substances that block MDM2-dependent degradation of p53
(e.g., Nutlin and MI-219 [100,101]). Many of these substances
have already been tested in HCC models (e.g., PRIMA-1 [102],
Nutlin [103], 10058-F4 [96], and YC-1 [98]) showing promising
preclinical anti-tumorigenic effects. In case of Nutlin, a ﬁrst clin-
ical trial for the treatment of retinoblastoma has been initiated.Gene therapeutic approaches
Both retroviral and adenoviral approaches have been established
for the delivery of proteins and peptides in tumor cells. However,
because genomic retrovirus integration is believed to increase the
risk of tumor development in patients, most approaches focussed
on adenovirus-based strategies. One example of the successful
application of this method is the restoration of p53wt function
in tumor cells. Replication-impaired, non-integrating adenoviral
vectors carrying p53 under the control of the CMV promoter
has been approved in China (trademarked as Gendicine) and used2 vol. 57 j 186–195 191
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for the treatment of head and neck cancer [104]. Although not
approved by the FDA, a recent report from China demonstrated
that combination of Gendicine with radiotherapy showed high
response rate and increased survival in HCC patients [105].
Oncolytic virotherapeutics link the loss of p53 activity with
anti-neoplastic viral replication [106]. Since adenoviral E1B
inhibits p53wt activity and prevents infected cells from undergo-
ing apoptosis, the infection with E1B-deﬁcient viruses should
selectively kill p53mut or p53del tumor cells as employed in the
genetically engineered adenovirus Onyx-015 (with E1B-55K dele-
tion), which replicates speciﬁcally in p53 dysfunctional cells
[107]. Although ﬁrst trials demonstrated that Onyx-015 was tol-
erated well, and in combination with chemotherapy resulted in
some anti-tumoral activity [108], other studies casted doubts
about virus-speciﬁcity and therefore challenged the applicability
of E1B-55K/p53-dependent virotherapy [109]. In 2005, H101 was
approved in China (trademarked as Oncorine) which showed a
high degree of similarity with Onyx-015 [104]. A recent HCC case
report demonstrated beneﬁcial effects in a patient with recurrent
HCC after administration of TACE and H101 [110].
Recently, p53-dependent oncolytic viruses (Adp53sensor)
without any alterations in the E1B gene have been designed; here
p53mut or p53del selectivity was achieved by chemotherapy-
induced and p53-dependent expression of the transcriptional
repressor Gal4-KRAB, which itself inhibits viral E1A gene expres-
sion [111]. This system allowed efﬁcient viral replication in p53
dysfunctional tumor cells but not in cells with p53wt in vitro as
well as in vivo and showed a favourable liver toxicity proﬁle in
animals. Importantly, p63 and p73 isoforms were not sufﬁcient
to compromise Adp53sensor replication, demonstrating that this
approach was not restricted by other p53 family members in HCC
cells [111]. Thus, novel virotherapeutic strategies based on p53
integrity may overcome limitations of previous oncolytic
approaches and some studies suggested that HCC cells are prom-
ising targets [112,113].
Because this methodological approach links anti-tumorigenic
viral activity with the activity of oncogenic transcriptional regu-
lators and does not rely on the perturbation of protein/protein
and protein/DNA interaction, it represents a promising tool for
targeting non-druggable factors. Indeed, different studies demon-
strated the applicability of this method in cells with aberrant
STAT3 [114], HIF-1a [115,116], E2F [117], and b-catenin [118]
activity. In case of E2F, oncolytic adenoviruses using the tumor-
speciﬁc E2F1 promoter have successfully been tested in HCC cells
[117].Outlook
Based on genomic and transcriptomic information on human
HCC, a deﬁned number of transcriptional regulators, which are
predominantly activated in a group of phenotypically aggressive
HCCs, have been identiﬁed. Despite methodological limitations,
for some of these factors, ﬁrst perturbation strategies have been
successfully established and tested in HCC; however, in order
to improve their applicability and to avoid the development of
resistance in tumor cells, more transcriptional regulators have
to be made druggable. In this regard, it will be important to over-
come the increased challenges of lead substance optimization
imposed by the lack of active enzymatic centres in transcription192 Journal of Hepatology 201factors and transcriptional co-factors. Optimized tumor cell
targeting will probably further improve the activity and speciﬁc-
ity of anti-tumoral viruses.
It is worth mentioning, that previous proﬁling data suggested
the existence of HCC derived from hepatic progenitor cells/stem
cells of the liver [22], and it is now believed that about 40% of
all HCCs are of clonal origin and therefore potentially arise from
progenitor/stem cells [119]. These cells perpetuate themselves
through self-renewal and are responsible for tumor formation
and progression through activation of distinct pathways includ-
ing, e.g., TGFb-/IL6-, Notch-, and Hedgehog signalling [120,121].
In addition, transcriptional regulators and pathways identiﬁed
by functional genomics such as Wnt/b-catenin and c-Myc are
central regulators of stemness. Therefore, targeting additional
transcriptional regulators (e.g., SMADs, NICD, or Gli) might cover
the whole ﬁeld of potential targets in terms of pathways and spe-
ciﬁc hepatocytic cell types.Financial support
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